State Street’s Vor Biopharma VOR Stock Holding History

State Street’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$37.6M	Sell	1,969,801 -646,535	-25%	-$13.8M	﹤0.01%	1997
2026 Q2	$48.2M	Buy	2,616,336 +1,497,878	+134%	+$22.7M	﹤0.01%	1878
2026 Q1	$20M	Buy	1,118,458 +1,027,405	+1,128%	+$14.5M	﹤0.01%	2239
2025 Q4	$1.19M	Buy	91,053 +81,999	+906%	+$1.53M	﹤0.01%	3483
2025 Q3	$441K	Buy	9,054 +3,257	+56%	+$131K	﹤0.01%	3690
2025 Q2	$188K	Hold	5,797	–	–	﹤0.01%	3853
2025 Q1	$83.2K	Hold	5,797	–	–	﹤0.01%	4006
2024 Q4	$129K	Hold	5,797	–	–	﹤0.01%	3941
2024 Q3	$81.2K	Hold	5,797	–	–	﹤0.01%	4017
2024 Q2	$116K	Sell	5,797 -27,088	-82%	-$876K	﹤0.01%	3964
2024 Q1	$1.56M	Buy	32,885 +2,485	+8%	+$109K	﹤0.01%	3356
2023 Q4	$1.37M	Buy	30,400 +105	+0.3%	+$4.33K	﹤0.01%	3410
2023 Q3	$1.28M	Sell	30,295 -1,169	-4%	-$63.4K	﹤0.01%	3461
2023 Q2	$1.94M	Buy	31,464 +28,908	+1,131%	+$2.64M	﹤0.01%	3424
2023 Q1	$275K	Buy	2,556 +60	+2%	+$6.65K	﹤0.01%	3954
2022 Q4	$332K	Buy	2,496 +435	+21%	+$43K	﹤0.01%	3909
2022 Q3	$164K	Hold	2,061	–	–	﹤0.01%	4223
2022 Q2	$205K	Sell	2,061 -12,093	-85%	-$1.24M	﹤0.01%	4184
2022 Q1	$1.71M	Buy	14,154 +895	+7%	+$152K	﹤0.01%	3628
2021 Q4	$3.08M	Buy	13,259 +1,453	+12%	+$419K	﹤0.01%	3477
2021 Q3	$3.7M	Buy	11,806 +1,716	+17%	+$510K	﹤0.01%	3390
2021 Q2	$3.76M	Buy	10,090 +1,613	+19%	+$796K	﹤0.01%	3371
2021 Q1	$7.31M	Buy	+8,477	New	+$7.17M	﹤0.01%	2878

Other funds holding VOR

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Axiom Investors Greenwich, Connecticut $14B AUM 51.58% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

State Street's VOR Position: Q3 2026 in Review

State Street reduced its Vor Biopharma (VOR) stake by 25% in Q3 2026, selling an estimated $13.8M and leaving 1,969,801 shares worth $37.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

State Street first reported a position in VOR in Q1 2021 and has held it in 23 quarters since. The position peaked at $48.2M in Q2 2026. 76 funds tracked by Wall St. Rank hold VOR as of Q3 2026.

State Street held 1,969,801 shares of Vor Biopharma worth $37.6M as of Q3 2026.
State Street sold 646,535 Vor Biopharma shares in Q3 2026, an estimated $13.8M.
Vor Biopharma made up ﹤0.01% of State Street's portfolio in Q3 2026, its #1997 holding.
State Street first reported a position in Vor Biopharma in Q1 2021 and has held it in 23 quarters since.
State Street's Vor Biopharma position peaked at $48.2M in Q2 2026.
76 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.